Pharmaceutical

MediLink and Roche partner on cancer drug development

MediLink Therapeutics has signed a global partnership and licence deal with Roche to develop YL211 for solid tumours.

Jan 3, 2024 - 18:00
MediLink and Roche partner on cancer drug development
MediLink Therapeutics has signed a global partnership and licence deal with Roche to develop YL211 for solid tumours.
Read the original article

Tags:

Previous Article

EMA validates BMS’s repotrectinib application to treat cancer

Next Article

PDS-01ADC by PDS Biotechnology for Colorectal Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AI is a pillar of tomorrow’s healthcare system, but limitations remain

AI is a pillar of tomorrow’s healthcare system, but lim...

Sep 29, 2023

Senate confirms Monica Bertagnolli as NIH director

Senate confirms Monica Bertagnolli as NIH director

Nov 7, 2023

Listen: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech’s slump

Listen: Who discovered GLP-1? Plus: BrainStorm at the F...

Sep 28, 2023